{"DataElement":{"publicId":"7297559","version":"1","preferredName":"No Medical History Exception Skin Basal Cell Carcinoma Malignant Neoplasm CPTAC Indicator","preferredDefinition":"A response to indicate whether the candidate does not have a prior history of malignancies with the exception of basal cell skin cancer.","longName":"7297556v1.0:6841630v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7297556","version":"1","preferredName":"No Medical History Exception Skin Basal Cell Carcinoma Malignant Neoplasm","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction._A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies._An instance that does not conform to a rule or generalization._The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","longName":"7297553v1.0:7297554v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"7297553","version":"1","preferredName":"Negation Personal Medical History","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.:A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","longName":"C25594:C18772","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Personal Medical History","conceptCode":"C18772","definition":"A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6910D8C-8E1C-373A-E053-4EBD850A2AB2","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"ONEDATA","dateModified":"2020-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7297554","version":"1","preferredName":"Exception Skin Basal Cell Carcinoma Malignant Neoplasm","preferredDefinition":"An instance that does not conform to a rule or generalization.:The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","longName":"C54420:C2921:C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exception","conceptCode":"C54420","definition":"An instance that does not conform to a rule or generalization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Skin Basal Cell Carcinoma","conceptCode":"C2921","definition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6910D8C-8E2E-373A-E053-4EBD850A2AB2","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"ONEDATA","dateModified":"2020-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6910D8C-8E3F-373A-E053-4EBD850A2AB2","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"KNABLEJ","dateModified":"2020-06-12","changeDescription":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6841630","version":"1","preferredName":"CPTAC Yes No Unk Indicator","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"6841630v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3104212","version":"1","preferredName":"Unknown","longName":"3104212v1.00","preferredDefinition":"Not known, observed, recorded; or reported as unknown by the data contributor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F3C580-06F4-1DC3-E040-BB89AD434E7E","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":"Concept annotated for UPitt/TCGA.  Ylu, 01/30/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0FF8F1-5A82-3678-E053-F662850A4C36","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"ONEDATA","dateModified":"2019-08-01","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"5682957","version":"1","preferredName":"Yes","longName":"5682957","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4DAE-2A6B-7561-E053-F662850A0EBD","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"DWARZEL","dateModified":"2018-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8EFB6B26-0CA9-5A31-E053-F662850A5C7D","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"5682943","version":"1","preferredName":"No","longName":"5682943","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9AC2-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"DWARZEL","dateModified":"2018-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8EFB6B26-0CB3-5A31-E053-F662850A5C7D","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","deletedIndicator":"No"},{"value":"Unknown: Could not be determined or unsure","valueDescription":"Indeterminate or Unknown","ValueMeaning":{"publicId":"6841632","version":"1","preferredName":"Indeterminate or Unknown","longName":"6841632","preferredDefinition":"An indication that something is indeterminate or unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate or Unknown","conceptCode":"C157157","definition":"An indication that something is indeterminate or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C86-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A782DA4-CE67-084E-E053-F662850AB283","beginDate":"2019-07-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6841629","version":"1","preferredName":"Clinical Proteomic Tumor Analysis Consortium Indicator","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C157175:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Proteomic Tumor Analysis Consortium","conceptCode":"C157175","definition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C5B-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C6C-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"GDEEN","dateModified":"2023-11-14","changeDescription":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  7-31-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6776734","version":"1","longName":"All Generic CRFs","context":"OCCPR"},{"publicId":"7203746","version":"1","longName":"Screening and Eligibility","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Candidate does not have prior","type":"Preferred Question Text","description":"Candidate does not have prior history of other malignancies within the past 12 months, with the exception of basal cell skin cancer","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6910D8C-8E67-373A-E053-4EBD850A2AB2","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-08-03","changeDescription":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"8/3/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"}}